Form D · Biotechnology
Simbryo Technologies, Inc.
Houston, TX · CIK 0002147331
Offering snapshot reported Jul 27, 2026 · SEC filing
- Reported sold
- $5.25M Offering amount: $5.25M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 26, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2026 | Initial | $5,250,972 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-592230
Source: Form D, filed Jul 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yael Katz | Director, Executive |
| Andrea Mazzocchi | Director |
| Stephen Rooks | Director |
| Aryeh Warmflash | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4430 Osby Dr.
Houston, TX, 77096
Phone: 512-763-2196
Houston, TX, 77096
Phone: 512-763-2196